For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Travere Therapeutics Inc’s stock clocked out at $17.44, up 1.22% from its previous closing price of $17.23. In other words, the price has increased by $1.22 from its previous closing price. On the day, 1.12 million shares were traded. TVTX stock price reached its highest trading level at $17.54 during the session, while it also had its lowest trading level at $17.13.
Ratios:
To gain a deeper understanding of TVTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 12.20 whereas as Long-Term Debt/Eq ratio is at 9.93.
On June 11, 2025, Citigroup reiterated its Buy rating and also upped its target price recommendation from $35 to $32.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 01 ’25 when Inrig Jula sold 815 shares for $14.65 per share. The transaction valued at 11,940 led to the insider holds 88,787 shares of the business.
Cline Christopher R. sold 1,784 shares of TVTX for $37,553 on May 05 ’25. The CHIEF FINANCIAL OFFICER now owns 93,126 shares after completing the transaction at $21.05 per share. On May 05 ’25, another insider, Dube Eric M, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 18,924 shares for $21.05 each. As a result, the insider received 398,350 and left with 419,173 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 1554579072 and an Enterprise Value of 1634614400. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 47.45. Its current Enterprise Value per Revenue stands at 4.896 whereas that against EBITDA is -13.561.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.79, which has changed by 0.93134 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $8.83. The 50-Day Moving Average of the stock is 7.94%, while the 200-Day Moving Average is calculated to be -3.01%.
Shares Statistics:
It appears that TVTX traded 1.50M shares on average per day over the past three months and 1536620 shares per day over the past ten days. A total of 89.10M shares are outstanding, with a floating share count of 86.76M. Insiders hold about 2.67% of the company’s shares, while institutions hold 116.04% stake in the company. Shares short for TVTX as of 1755216000 were 12107746 with a Short Ratio of 7.10, compared to 1752537600 on 12859589. Therefore, it implies a Short% of Shares Outstanding of 12107746 and a Short% of Float of 13.68.
Earnings Estimates
The current assessment of Travere Therapeutics Inc (TVTX) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.01, with high estimates of $0.29 and low estimates of -$0.17.
Analysts are recommending an EPS of between $0.08 and -$1.04 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is $1.25, with 8.0 analysts recommending between $2.1 and $0.09.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $106.64M. It ranges from a high estimate of $116.01M to a low estimate of $99.5M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $62.9MFor the next quarter, 13 analysts are estimating revenue of $118.74M. There is a high estimate of $151.1M for the next quarter, whereas the lowest estimate is $103M.
A total of 13 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $458.5M, while the lowest revenue estimate was $398.68M, resulting in an average revenue estimate of $420.5M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $588.21M in the next fiscal year. The high estimate is $795.9M and the low estimate is $468.83M.
